Operating
Deferred Taxes
Neurocrine Biosciences Deferred Taxes decreased by 226.8% to -$61.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 346.0%, from -$13.70M to -$61.10M. Over 2 years (FY 2022 to FY 2025), Deferred Taxes shows an upward trend with a 194.3% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityVolatile
First reportedQ1 2018
Last reportedQ1 2026May 5, 2026
How to read this metric
Positive values indicate tax benefits that improve cash flow, while negative values indicate cash tax outflows exceeding accounting expense.
Detailed definition
This reflects the difference between income tax expense recognized in the financial statements and the actual tax payabl...
Peer comparison
Common across all industries; highly dependent on specific tax jurisdictions and capital expenditure cycles.
Metric ID:
deferred_income_taxesHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.50M | $5.70M | -$300.00K | -$3.10M | $9.00M | $13.50M | -$31.60M | -$41.50M | -$4.20M | -$15.60M | -$41.30M | -$34.90M | -$31.30M | -$13.70M | -$37.40M | $168.30M | $48.20M | -$61.10M |
| QoQ Change | — | -40.0% | -105.3% | -933.3% | +390.3% | +50.0% | -334.1% | -31.3% | +89.9% | -271.4% | -164.7% | +15.5% | +10.3% | +56.2% | -173.0% | +550.0% | -71.4% | -226.8% |
| YoY Change | — | — | — | -132.6% | +57.9% | — | <-999% | <-999% | -146.7% | +50.6% | +0.5% | -731.0% | — | +12.2% | +9.4% | +582.2% | +254.0% | -346.0% |
Range-$61.10M – $168.30M
CAGR+55.0%
Avg YoY Growth-927.8%
Median YoY Growth+0.5%
Current Streak2 quarters decline
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $6.80M | $52.00M | $82.30M | $85.70M | $48.90M |
| Total | -$13.70M | -$37.40M | $168.30M | $48.20M | -$61.10M |
Deferred Taxes at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's deferred taxes?
- Neurocrine Biosciences (NBIX) reported deferred taxes of -$61.10M in Q1 2026.
- How has Neurocrine Biosciences's deferred taxes changed year-over-year?
- Neurocrine Biosciences's deferred taxes decreased by 346.0% year-over-year, from -$13.70M to -$61.10M.
- What is the long-term trend for Neurocrine Biosciences's deferred taxes?
- Over 2 years (2022 to 2025), Neurocrine Biosciences's deferred taxes has grown at a 194.3% compound annual growth rate (CAGR), from $19.10M to $165.40M.
- What does deferred taxes mean?
- The difference between tax reported on the income statement and actual cash taxes paid.